[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/pages/docs/Risk/index.md) >> Individual ID:PBN__Risk_431 

# __Development of drugs__

## Articles mentionning the risk

* [Current knowledge of COVID-19: Advances, challenges and future perspectives](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_118.md)

## Category to which it belongs

* [Inadequate resources, staff, facilities, training, coordination, and preparedness contribute to the inefficient and ineffective response to various challenges and needs.](https://github.com/mm80843/T3.5/blob/pages/PBNCategory/PBN__PBNCategory_78.md)

## Closest similar item

* [Delayed drug development](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_466.md)
* [Identification of effective drug compounds](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1783.md)
* [Impact on healthcare systems and pharmaceutical industry](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2684.md)
* [Lack of access to pharmaceutical interventions](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1589.md)
* [Lack of accessibility of pharmaceutical interventions in developing countries](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2996.md)
* [Lack of drug therapy options](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_727.md)
* [Lack of effective drugs](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1151.md)
* [Lack of effective pharmaceutical response](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1139.md)
* [Missing information in existing drug ontologies](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_40.md)
* [Slow drug development](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1794.md)

## Description of the risk

Efforts are being made to develop effective drugs for the treatment of COVID-19.

## Is the risk affecting GBN scales

* [No](https://github.com/mm80843/T3.5/blob/pages/ISO_Scale/PBN__ISO_Scale_0.md)

## Mitigations of this risk

* [Continued research and development of drugs for the treatment of covid-19.](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_3063.md)
* [Drug development](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_599.md)

## Name of the risk

Limited treatment options and control measures without effective drugs.

## People affected by this risk

* [Healthcare providers](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_31.md)
* [Patients](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_121.md)

## Stakeholders who can mitigate this risk

* [Pharmaceutical companies](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_46.md)
* [Scientists](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_124.md)

## Technologies linked to the risk

* [Clinical trials](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_1960.md)
* [Research on potential therapeutic options](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_1959.md)

## Type of impact of the risk (according to ISO37100)

* [Innovation, creativity and research](https://github.com/mm80843/T3.5/blob/pages/ISO_Purpose/PBN__ISO_Purpose_2.md)

## Type of purpose of the risk (according to ISO37100)

* [Innovation, creativity and research](https://github.com/mm80843/T3.5/blob/pages/ISO_Impact/PBN__ISO_Impact_8.md)

## Type of the risk

* [Physical](https://github.com/mm80843/T3.5/blob/pages/RiskHealth/PBN__RiskHealth_0.md)

## Property: has_RiskType

* [Technological](https://github.com/mm80843/T3.5/blob/pages/RiskType/PBN__RiskType_5.md)

